US 10526330
JAK kinase inhibitor compounds for treatment of respiratory disease
granted A61KA61K31/416A61K31/437
Quick answer
US patent 10526330 (JAK kinase inhibitor compounds for treatment of respiratory disease) held by Theravance Biopharma R&D IP, LLC expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K31/416, A61K31/437, A61P, A61P11/00